
Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial
Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial, assessing the safety and efficacy of ifinatamab deruxtecan (I-DXd) in individuals with unresectable advanced or metastatic oesophageal squamous cell …